Toggle menu
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.

Page values for "Meloxicam"

From Pharmacopedia
More actions

"Medicines" values

1 row is stored for this page
FieldField typeValue
genericStringMeloxicam
brandStringMobic, Vivlodex (lower-dose capsules), Anjeso (IV)
structureFile
classesList of String, delimiter: ,[[:Category:NSAIDs|Non-steroidal anti-inflammatory (NSAID preferential COX-2)]] [[:Category:Analgesics|Analgesic]]
mechanismString'"`UNIQ--vote-00000019-QINU`"' Once-daily dosing is a clinical advantage over short-half-life NSAIDs'"`UNIQ--ref-0000001A-QINU`"'.
usesString'"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"'
starting_doseString7.5 mg PO once daily; titrate to 15 mg daily if needed. Vivlodex 5 mg PO once daily, max 10 mg
preparationsStringTablets 7.5, 15 mg (Mobic); capsules 5, 10 mg (Vivlodex); oral suspension 7.5 mg/5 mL; injection 30 mg/mL (Anjeso)
fda_maxString15 mg/day (oral); 30 mg IV once daily (Anjeso)
pill_idText
routesList of String, delimiter: ,Oral intravenous
onsetStringAnalgesic effect within hours; full anti-inflammatory effect over 1-2 weeks
durationString24 hours (once-daily dosing supported by long half-life)
halflifeString15-20 hours'"`UNIQ--ref-00000020-QINU`"'
bioavailabilityString~89% (oral)'"`UNIQ--ref-00000021-QINU`"'
pregnancyStringAvoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning (fetal renal dysfunction, oligohydramnios); contraindicated from 30 weeks (risk of premature ductus arteriosus closure)'"`UNIQ--ref-00000022-QINU`"'
legalString[[USLegal:Prescription only|Rx-only]] in US